Amylyx Pharmaceuticals Inc

NASDAQ:AMLXUnited States

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.

Contact Information

Headquarters

43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141

Phone

617-682-0917

Fax

302-636-5454

Executives

Chair of the Board of Directors

George Milne

Co-Chief Executive Officer, Director

Joshua Cohen

Co-Chief Executive Officer, Director

Justin Klee

Chief Financial Officer

James Frates

Chief Legal Officer and General Counsel

Gina Mazzariello